0.688 USD
-0.02 (-3.08%)
0.6811 USD
-0.01 (-1%)
We assign a fundamental rating of 2 out of 10 to TRIB. TRIB was compared to 186 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TRIB have multiple concerns. TRIB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year TRIB has reported negative net income.
- TRIB had a negative operating cash flow in the past year.
- In the past 5 years TRIB reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
1.2 Ratios
- With a Return On Assets value of -30.78%, TRIB perfoms like the industry average, outperforming 43.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.78% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 34.83%, TRIB is doing worse than 73.12% of the companies in the same industry.
- In the last couple of years the Gross Margin of TRIB has declined.
- The Profit Margin and Operating Margin are not available for TRIB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
2. Health
2.1 Basic Checks
- TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
- TRIB has about the same amout of shares outstanding than it did 1 year ago.
- TRIB has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, TRIB has an improved debt to assets ratio.
2.2 Solvency
- TRIB has an Altman-Z score of -0.89. This is a bad value and indicates that TRIB is not financially healthy and even has some risk of bankruptcy.
- TRIB's Altman-Z score of -0.89 is in line compared to the rest of the industry. TRIB outperforms 41.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.89 |
ROIC/WACCN/A
WACC7.05%
2.3 Liquidity
- TRIB has a Current Ratio of 1.28. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
- TRIB has a worse Current ratio (1.28) than 80.11% of its industry peers.
- A Quick Ratio of 0.68 indicates that TRIB may have some problems paying its short term obligations.
- TRIB has a Quick ratio of 0.68. This is amonst the worse of the industry: TRIB underperforms 87.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.68 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 16.67% over the past year.
- Looking at the last year, TRIB shows a quite strong growth in Revenue. The Revenue has grown by 8.31% in the last year.
- The Revenue has been decreasing by -7.41% on average over the past years.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%
3.2 Future
- TRIB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.68% yearly.
- Based on estimates for the next years, TRIB will show a quite strong growth in Revenue. The Revenue will grow by 11.62% on average per year.
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- TRIB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year TRIB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TRIB's earnings are expected to grow with 34.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for TRIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.688
-0.02 (-3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)04-03 2026-04-03/bmo
Inst Owners24.88%
Inst Owner Change0.55%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.21M
Revenue(TTM)61.56M
Net Income(TTM)-31.79M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-128.03%
Min EPS beat(2)-272.55%
Max EPS beat(2)16.49%
EPS beat(4)1
Avg EPS beat(4)-116.51%
Min EPS beat(4)-272.55%
Max EPS beat(4)16.49%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.88%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-5.78%
Revenue beat(4)0
Avg Revenue beat(4)-6.76%
Min Revenue beat(4)-9.97%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-7.57%
Revenue beat(12)1
Avg Revenue beat(12)-11.44%
Revenue beat(16)3
Avg Revenue beat(16)-13.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS3.21
BVpS-1.83
TBVpS-4.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.78% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 34.83% | ||
| FCFM | N/A |
ROA(3y)-38.57%
ROA(5y)-23.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.46%
GM growth 5Y-3.74%
F-Score4
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 539.63% | ||
| Cap/Sales | 16.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.68 | ||
| Altman-Z | -0.89 |
F-Score4
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)316%
Cap/Depr(5y)319.23%
Cap/Sales(3y)10.22%
Cap/Sales(5y)10.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16%
EPS Next Y65.8%
EPS Next 2Y34.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.31%
Revenue growth 3Y-8.8%
Revenue growth 5Y-7.41%
Sales Q2Q%18.09%
Revenue Next Year10.13%
Revenue Next 2Y11.62%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.74%
OCF growth 3YN/A
OCF growth 5YN/A
TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ
What is the fundamental rating for TRIB stock?
ChartMill assigns a fundamental rating of 2 / 10 to TRIB.
Can you provide the valuation status for TRINITY BIOTECH PLC-SPON ADR?
ChartMill assigns a valuation rating of 1 / 10 to TRINITY BIOTECH PLC-SPON ADR (TRIB). This can be considered as Overvalued.
Can you provide the profitability details for TRINITY BIOTECH PLC-SPON ADR?
TRINITY BIOTECH PLC-SPON ADR (TRIB) has a profitability rating of 1 / 10.
Is the dividend of TRINITY BIOTECH PLC-SPON ADR sustainable?
The dividend rating of TRINITY BIOTECH PLC-SPON ADR (TRIB) is 0 / 10 and the dividend payout ratio is 0%.